MILFORD, Mass., June 1, 2026 /PRNewswire/ -- 74th ASMS Conference on Mass Spectrometry and Allied Topics— Waters Corporation (NYSE: WAT) today announced the launch of the Waters Cyclic IMS P20 Mass Spectrometer, a high-resolution structural and spatial omics platform designed to help scientists see biology more clearly, and act on it faster. Combining multipass Cyclic Ion Mobility Spectrometry with an enhanced suite of fragmentation, probing, and imaging capabilities, this unique and powerful instrument delivers confident insights for the early detection of disease signals, from protein misfolding to post-translational modifications. The system's full‑spectrum molecular imaging unlocks unparalleled visualization within a single experiment1 to accelerate discovery and development, and power deeper understanding of complex biology.
"Waters recognizes that advanced tools for structural and spatial omics play a critical role in delivering therapeutic breakthroughs," said James Hallam, Vice President & General Manager, Liquid Chromatography-Mass Spectrometry, Waters Analytical Sciences, Waters Corporation. "With its powerful fusion of capabilities, the Cyclic IMS P20 MS delivers a previously unattainable view into subtle molecular differences, unlocking a new level of understanding of the mechanisms that drive disease and advancing next‑generation discovery."
As researchers pursue larger and more heterogeneous therapeutic targets, analytical workflows need higher sensitivity, higher structural resolution, and easier-to-adopt methods. The Cyclic IMS P20 Mass Spectrometer meets that need with a more than a 10-fold increase in MS/MS sensitivity compared to its predecessor,2 an upper mass range extended by more than 50% to over 100 kDa,3 and a set of complementary structural probing approaches, including tandem ion mobility spectrometry (IMSn), electron-capture dissociation (ECD), surface-induced dissociation (SID), and collision-induced unfolding (CIU) – delivering the most comprehensive spatial and structural molecular view within a single platform.
"My lab studies proteins involved in misfoldings that drive human disease, which are notoriously difficult to characterize. We leverage the advanced capabilities of Cyclic IMS P20 MS to perform complex tandem ion mobility experiments on low‑abundance forms of a key molecule involved in the pathogenesis of Type II diabetes," said Kostas Thalassinos, Ph.D., Professor of Mass Spectrometry and Academic Lead, Institute of Structural and Molecular Biology, University College London. "The increase in sensitivity delivered by the new functionality is truly remarkable. It stands to significantly accelerate our analyses, potentially by an order of magnitude, and enables us to probe critical low‑abundance species in far greater detail. These rare molecular populations are essential for delineating the mechanisms that drive human disease."
The Cyclic IMS P20 Mass Spectrometer also brings Matrix-Assisted Laser Desorption/Ionization (MALDI) and Desorption Electrospray Ionization (DESI) imaging sources together in one system, pioneering their combination with advanced multipass cyclic ion mobility and IMS separation to help researchers see more, with greater clarity, directly in their samples. This unique approach broadens coverage across small molecules, lipids, peptides, and proteins, while separating isobaric and stereoisomeric compounds. Additionally, the system delivers multi-dimensional insights that elucidate links between molecular composition and the tissue microenvironment, supporting biomarker identification directly from tissue. These rich, easily-interpreted molecular maps provide increased confidence in lipidomics, drug and metabolite localization, translational research, and other experiments requiring visualization.
The Waters Cyclic IMS P20 Mass Spectrometer will be showcased at ASMS 2026 and is expected to be available globally beginning September 2026. For more information or to request a demo, visit product page.
Additional Resources:
Waters and Cyclic are trademarks of Waters Corporation or its affiliates. All other trademarks are the property of their respective owners.
The P in Cyclic IMS P20 denotes Premium, the highest performance tier from Waters, and 20 reflects the platform's evolution from the SELECT SERIES lineage under Waters' new product naming convention.
About Waters Corporation:
Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/about.
References:
Contact:
Molly Gluck
Head of External Communications
Waters Corporation
508.498.9732
molly_gluck@waters.com
Photo - https://mma.prnewswire.com/media/2991658/Waters_Cyclic_IMS_P20.jpg
Logo - https://mma.prnewswire.com/media/2071755/Waters_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/waters-unveils-cyclic-ims-p20-ms-the-new-benchmark-in-structural-and-spatial-omics-302786911.html
Die von US-Präsident Donald Trump angekündigten Zölle von 25 Prozent auf Neuwagenimporte aus der Europäischen Union würden nach Einschätzung von Branchenexperten vor allem die deutsche Autoindustrie treffen. Berechnungen des Center Automotive Research (CAR) in Bochum zufolge kämen allein auf die Autoproduktion in Deutschland zusätzliche Belastungen von rund 2,5 Milliarden Euro pro Jahr zu. Hinzu kämen weitere Kosten für US-Exporte deutscher Hersteller aus Werken in anderen EU-Staaten.
Obwohl sich die Maßnahmen formal gegen die gesamte EU richten, sieht CAR-Direktor Ferdinand Dudenhöffer insbesondere Deutschland im Visier Washingtons. Die Exporte anderer ausländischer Autobauer in die USA seien „unwesentlich“, sagte er und sprach mit Blick auf die neuen Zoll-Drohungen vom möglichen Beginn eines „Wirtschaftskriegs gegen Deutschland“. Die Maßnahmen würden die Hersteller jedoch unterschiedlich hart treffen, abhängig von ihrer Produktionsstruktur und Präsenz in den Vereinigten Staaten.
Relativ besser gestellt wären demnach Konzerne wie BMW und Mercedes-Benz, die über umfangreiche Produktionskapazitäten in den USA verfügen. In ihren US-Werken fertigen sie vor allem SUV-Modelle, die den Großteil ihrer Verkäufe auf dem US-Markt ausmachen. Diese lokale Produktion wirkt nach Einschätzung Dudenhöffers wie ein „Zollschutz“, weil in den USA montierte Fahrzeuge nicht unter die geplanten Importzölle auf Neuwagen aus der EU fallen würden.
Deutlich verwundbarer wären dagegen Marken wie Audi und Porsche, die ihre Fahrzeuge bislang weitgehend aus Europa in die USA liefern. Für sie könnten die neuen Einfuhrabgaben ein Anreiz sein, Pläne zum Aufbau eigener Produktionsstätten in den Vereinigten Staaten zu beschleunigen. Vollständig auffangen können die Hersteller die zusätzlichen Kosten nach Einschätzung des CAR-Instituts jedoch nicht. Ein Teil der Belastungen dürfte über Preiserhöhungen an die US-Käufer weitergegeben werden. Dank der starken Markenbindung rechnet Dudenhöffer zwar nicht mit einem abrupten Nachfrageeinbruch, die deutschen Autobauer stünden jedoch vor der Herausforderung, ihre Preissetzung und Standortstrategie zügig an die neue handelspolitische Lage anzupassen.
